The 30 second version: the sign in sheet tells you a name. Ask the role. The CRA checks the study and sells nothing. The drug rep sells an approved drug and stays out of the study. The MSL takes the science questions the rep can't answer. Written for new coordinators, and for anyone who has wondered why the drug industry is in the building at all.

In this file:

·        The CRA, who checks the study and sells nothing

·        The drug rep, who sells and stays out of the study

·        The MSL, who takes the science questions the rep can't answer

·        Where the line is, and what to do when someone leans on it

Mira signed in at 8:30 with a rolling case of binders and a laptop. It was a monitoring visit, and she'd booked the small conference room until 4.

At 11:45 a man in a sport coat came through the same door with 2 catering trays. His name was Charles. He sold a heart medicine Dr. Reyes prescribed in clinic, and he'd set up lunch for the office weeks ago.

He signed the same sheet Mira had. Then he smiled at Nani and asked, friendly as anything, "How's the study going? Enrolling well?"

Charles worked for the company sponsoring the study. Mira worked for the CRO that company had hired to monitor it. Both of them, in a sense, came from the same place.

Nani said, "I'll leave that to the study team," handed him the lunch sign in sheet, and made a note to ask Mira about it at the end of the day.

Mira's answer took about 5 minutes. It's the rest of this issue.

The regulations put the job of watching a study on the sponsor. Under 21 CFR 312.50 the sponsor is responsible for "ensuring proper monitoring of the investigation(s)," and under 312.53(d) it has to pick a monitor "qualified by training and experience" to do it. A sponsor can hand that work to a CRO, which is why Mira's badge had a different company name on it.

The current Good Clinical Practice guideline, ICH E6(R3), says the aim of monitoring is to ensure participants' rights, safety and well being, and the reliability of the trial's results. In practice that means Mira checks what the site recorded against the original records, looks at consent forms, drug accountability and deviations, and writes a report on what she reviewed and what has to be fixed. Some of it happens on site and some of it remotely.

What she doesn't do matters just as much. She doesn't change the site's data; she asks the site to. And she doesn't sell. 21 CFR 312.7(a) says a sponsor, an investigator, and anyone acting for them "shall not represent in a promotional context that an investigational new drug is safe or effective." A CRA who started talking up the study drug would be crossing a line the regulations draw on purpose.

Charles's job is promotion, and promotion has tighter rules than most people expect. What he can say is tied to the drug's FDA approved labeling, the prescribing information. FDA's advertising rule, 21 CFR 202.1, says promotion can't suggest a use that isn't in that labeling and has to give a fair balance of risks alongside benefits, and FDA holds what reps say out loud to the same standard. The printed pieces reps hand out, called detailing pieces, count as labeling under the same rule.

That isn't theoretical. In 2018, FDA sent a company a letter over what one rep said at a single lunch presentation, where the statements played down risks and promoted an unapproved use. One lunch was enough.

Then there's the money. The industry's own code of conduct, last revised in 2022, keeps meals with a rep's presentation modest and in the office, and bans alcohol at company speaker programs. Meals Charles buys a doctor above a small threshold (the threshold changes each year, and CMS publishes it) are reported to the federal government and published in a public database called Open Payments, along with education items like textbooks. And knowingly paying a doctor to prescribe drugs paid for by Medicare, Medicaid or other federal programs is a felony under the Anti Kickback Statute, with fines up to $100,000 and up to 10 years in prison.

Notice what's not on that list: anything to do with the study. Charles sells a drug that's already approved. The study is about one that isn't.

Over lunch, Dr. Reyes asked Charles whether the heart medicine helped a kind of patient the label doesn't mention. Charles said he couldn't speak to that, and offered to have the company's medical team follow up.

That team usually includes a medical science liaison, an MSL. There's no regulatory definition of the job. The MSL Society describes it as a scientific role built on peer relationships with experts, and its 2022 survey found 77% of US MSLs hold a doctorate.

FDA's thinking on who answers a doctor's off label question is still a draft from 2011, and FDA has never withdrawn it. The draft guidance on unsolicited requests says the answer should come from medical or scientific staff "independent from sales or marketing departments," and that "sales and marketing personnel have no input on the content of responses." A 2025 final guidance on scientific information companies choose to share says it "should be separate from promotional communications." Neither says a rep can never talk science. Both say the science and the selling don't mix.

Here's the honest version: no single FDA regulation bars a sales rep from walking into a research site. The line comes from several places at once.

·        No promoting the study drug. 21 CFR 312.7(a), above.

·        Research kept apart from sales. Federal compliance guidance for drug makers, written in 2003 and still the current version, says companies "should insulate research grant making from sales and marketing influences," and treats research deals that start on the sales side as particularly suspect.

·        Investigator pay tied to work, not results. The industry's clinical trial principles say payment to investigators should be based on work performed and "should not be tied to the outcome of clinical trials."

·        Participant privacy. The consent form tells participants that monitors, auditors, the ethics board that approved the study and regulators like FDA may look at their records. Nothing on that list covers the sales side.

So Charles asking how enrollment is going isn't a crime. It's just a question the study team doesn't answer for the sales side, and most companies would rather he didn't ask. Nani's answer was the right one: polite, short, and pointed at the people whose job it is.

Copy this: the front desk rule. The sign in sheet tells you a name. Ask the role.
CRA: checks the study, sells nothing.
Rep: sells an approved drug, stays out of the study.
MSL: takes the science questions the rep can't answer.
A monitor is there because the study requires it, and she can see participant records because participants agreed to it. A rep is there for the clinic, not the study. If anyone from the sales side asks about enrollment, a participant or study results, a good default is: that's for the study team. Check your site's SOP for whether to let your PI or the monitor know it happened.

Know someone starting their first coordinator job? Copy the front desk rule and send it with one line: "Same sign in sheet, completely different jobs. Ask the role."

·        Three people from industry can visit a site, and each one answers to different rules.

·        The CRA carries out the sponsor's duty to monitor (21 CFR 312.50 to 312.56), checks records against the source, and can't promote the study drug (21 CFR 312.7(a)).

·        The drug rep promotes an approved drug, only within its labeling and with a fair balance of risks. Meals above a small threshold get reported to Open Payments.

·        The MSL answers the science questions. FDA's still draft 2011 guidance says off label questions should go to medical staff who are independent of sales.

·        No single rule keeps reps out of research. Federal guidance, the investigational drug rules and participant privacy all point the same way: the study stays with the study team.

Nani's 7 words at the front desk summed it up: "I'll leave that to the study team."

Reply to this email or leave a comment on the newsletter: coordinators, how does your site handle rep visits on a research day? Has anyone from the sales side ever asked you about a study? Every query gets read, and the best ones get answered in a future issue.

Know someone training for their first coordinator job? Send them this with one line: "The sign in sheet tells you a name. Ask the role. This explains who's who." Use your referral link below so the share counts. The Open Site File is written for exactly that person.

The Open Site File is one part of Root to Rx. Plain Talk opens in The Root Room, where a real health claim tries to work on someone, then takes it apart in plain language. The Roots, on LinkedIn and Substack, is a letter for the people whose family treats them as the medical desk. The Open Site File shows you the inside of the site. Different doors, one mission: more people who understand how medicine gets made.

·        Previous issue: Issue 20, when a PI asks you to backdate a consent

·        Related: Issue 8, what happens during a monitoring visit

·        Related: Issue 19, what a clinical research assistant does

·        For the people whose family treats them as the medical desk: The Roots, our weekly letter.

·        Why the rules read the way they do, and the history behind them: Version History.

·        Helping a patient or family member look for a study? A walkthrough of the public trial registries.

·        Patient materials, including a medication and supplement log modeled on the conmed logs used in trials: the Root to Rx shop.

·        21 CFR 312 Subpart D, Responsibilities of sponsors and investigators (eCFR)

·        21 CFR 312.7, Promotion of investigational drugs (eCFR)

·        ICH E6(R3) Good Clinical Practice, FDA final guidance, September 2025, section 3.11.4 on monitoring

·        FDA, A Risk Based Approach to Monitoring of Clinical Investigations: Questions and Answers. Final guidance, April 2023

·        21 CFR 202.1, Prescription drug advertisements (eCFR)

·        Faegre Drinker, FDA warns against sales representative false and misleading oral statements, October 2018

·        Loeb & Loeb, PhRMA revisions to the Code on Interactions with Health Care Professionals, effective January 1, 2022

·        42 USC 1320a-7b, Anti Kickback Statute (Cornell LII)

·        FDA, Responding to Unsolicited Requests for Off Label Information About Prescription Drugs and Medical Devices. Draft guidance, December 2011

·        FDA, Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers. Final guidance, January 2025

·        MSL Society, What is an MSL?

·        HHS OIG, Compliance Program Guidance for Pharmaceutical Manufacturers, 68 FR 23731, May 2003

·        CMS, Open Payments: Natures of Payment

·        CMS, Open Payments data overview

·        CMS, Open Payments data collection and reporting thresholds

·        PhRMA, Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results

•  •  •

The Open Site File is general education about how clinical research sites work. It is not regulatory, legal, or medical advice, and it is not tied to any specific study, sponsor, or employer. If you are in a trial, your study team and your own doctor are the right people to ask about your situation. Always follow your own site’s SOPs, your protocol, and your PI and QA team. Names and characters are invented composites.

Disclosure: The Open Site File is part of Root to Rx, published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.

Filed by Justin Yamashita, MSc., Open Label Media